BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Research Roundup: Genetic Variants Associated with Severe COVID-19 and More

  Researchers have now identified 16 new genetic variants associated with severe COVID-19. For that and more research stories, continue reading.

  March 11, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Business

  AbbVie, Richter Unite to Target Complex Neuropsychiatric Conditions

  The two companies will work closely to harness the abilities of dopamine receptor modulators to help patients living with complex neuropsychiatric conditions.

  March 11, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Capricor Ditches COVID-19 Vaccine Program to Focus on DMD

  Capricor Therapeutics announced less-than-stellar Q4 2021 and full-year 2021 financial results and said the company stopped efforts on its COVID-19 vaccine.

  March 11, 2022

   · 

  2 min read

   · 

  Hannah Chudleigh
• 

  Deals

  BeiGene, Zai Lab, Among Companies Facing Delisting From Wall Street

  The SEC said that Yum China, BeiGene, Zai Lab, HutchMed and ACM Research are all at risk if they do not give U.S. regulators access to their audit records.

  March 11, 2022

   · 

  3 min read

   · 

  Rosemary Scott
• 

  FDA

  Biosimilars Gain Headway in US with Approval of Kashiv’s Releuko

  Releuko is expected to launch in the third quarter of 2022 as a treatment for neutropenia, a low white blood cell condition experienced by chemotherapy patients.

  March 11, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Selecta Revives MMA Gene Therapy Program After FDA Lifts Hold

  Selecta Biosciences is moving forward with development efforts for its gene therapy program for methylmalonic acidemia after the FDA lifted the hold on its clinical trial on March 9.

  March 11, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Policy

  Opioid Overdose Victims Confront Purdue Pharma’s Sackler Family Following Latest Settlement

  More than two dozen people were given the opportunity to confront members of the Sackler family in a virtual environment and share the impactful pain opioid addiction caused their families.

  March 11, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  On the Brink, Orphazyme Announces Second Round of Layoffs

  The Orphazyme board of directors decided to cut 50% of its current global staff count after carefully considering its financial state.

  March 11, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  MorphoSys Eats $250M, Centralizes Operations in Germany

  The drop in value has prompted MorphoSys to make drastic changes, such as discontinuing its U.S. operations and abandoning several pipeline projects.

  March 11, 2022

   · 

  1 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  More Unique Therapeutic Possibilities Posed by Rare Human Genes

  The discovery of a unique, inheritable resistance to Ebola infection has inspired the development of therapeutics that may not only be effective against Ebola but against COVID-19, as well.

  March 11, 2022

   · 

  5 min read

   · 

  Kaylei Whalen